Core Viewpoint - Vireo Growth Inc. has successfully refinanced its existing senior secured debt and expanded its credit capacity, resulting in significant interest savings and a stronger financial position for the company [1][4][5]. Group 1: Refinancing Details - The company closed a $120 million self-syndicated first lien term loan with leading banks, which refinances all existing senior secured obligations and is secured by a first-priority lien on substantially all assets [2][4]. - The three-year facility has an interest rate of 8.3% (1-month SOFR + 4.0%) and allows for prepayment at any time without penalty [2][3]. - Additionally, a $33 million second lien term loan was closed, featuring a $50 million accordion to support future strategic initiatives, with an interest rate of prime + 5.5% [3][4]. Group 2: Financial Impact - The refinancing is expected to generate over $10 million in annual interest savings, thereby enhancing the company's financial position and long-term shareholder value [1][4]. - The combined financing of $153 million strengthens the company's balance sheet with over $100 million in cash [1][4]. Group 3: Strategic Context - The refinancing follows a series of mergers that expanded Vireo's operational footprint and market leadership, consolidating and optimizing debt across the platform [4][5]. - The initiative reflects disciplined capital planning and strong institutional demand, with the senior facility being significantly oversubscribed [5][6]. Group 4: Leadership and Confidence - Lenders expressed confidence in the company's operating model, financial strategy, and leadership continuity, particularly the ongoing role of CEO John Mazarakis [6][7]. - The strong response from lending partners indicates progress made by the company and confidence in its ability to execute its long-term strategy [7].

Core Viewpoint - AYR Wellness Inc. is facing potential ownership reclamation and sale of its subsidiary's equity interests due to alleged defaults under a Pledge Agreement, while simultaneously extending a waiver agreement to negotiate with senior lenders [1][2][3]. Group 1: Notification of Disposition and Defaults - AYR Wellness received a Notification of Disposition of Collateral from the Agent, indicating potential defaults under the Pledge Agreement [1][2]. - The Agent intends to reclaim and sell all equity interests in PA Natural Medicine LLC, which operates licensed medical cannabis dispensaries in Pennsylvania [2]. Group 2: Waiver Agreement and Extensions - The Second Amendment extends the temporary waiver period to July 11, 2025, allowing AYR additional time to negotiate with senior lenders [3]. - The Original Agreement provided a waiver for certain defaults related to the delay in filing interim financial statements and specific payment defaults [3][4]. - The extension does not permanently waive existing defaults but facilitates ongoing discussions to address financial obligations [4]. Group 3: Company Overview - AYR Wellness is a vertically integrated U.S. multi-state cannabis operator with over 90 licensed dispensaries and a portfolio of cannabis CPG brands [6]. - The company aims to deliver high-quality cannabis products while positively impacting its team members and communities [6].

Core Insights - Cronos Group Inc. is expanding its distribution of the PEACE NATURALS medical cannabis brand in Switzerland through a partnership with Dascoli Pharma AG, a Swiss company specializing in medical cannabis supply and distribution [1][2] - The partnership aims to provide high-quality medical cannabis to Swiss patients and aligns with Cronos' mission to offer borderless cannabis products in European medical markets [2] - Cronos will supply PEACE NATURALS-branded cannabis flower to Dascoli for distribution across its established medical network in Switzerland, marking a significant step in Cronos' international growth strategy [2] Company Overview - Cronos Group Inc. is a global cannabinoid company focused on advancing cannabis research, technology, and product development, with a diverse international brand portfolio including Spinach, PEACE NATURALS, and Lord Jones [4] - The company is committed to building disruptive intellectual property and enhancing the consumer experience through its iconic brand portfolio [4] Partner Overview - Dascoli Pharma AG is a Swiss pharmaceutical firm that focuses on medical cannabis manufacturing and distribution across wholesale and retail channels, providing compliant cannabinoid therapies to patients, pharmacies, and clinics [5] - Dascoli is recognized as a leading cannabinoid retailer in Switzerland, offering next-day home delivery services for patients [5] Product Availability - PEACE NATURALS medical cannabis products are now available in multiple countries, including Australia, Canada, Germany, Israel, Malta, Switzerland, and the UK [3]

Core Business Overview - Dogecoin Cash Inc. (DOGP) is a publicly traded company that operates in the cannabis telemedicine sector and blockchain innovation, holding a patented cannabis strain and product for hypertension treatment [6][7] - The company focuses on developing and commercializing cannabis-based products, including CBD-infused wellness solutions and pharmaceutical-grade formulations, while seeking to expand its portfolio through strategic partnerships and acquisitions [7] Blockchain and Digital Asset Strategy - Dogecoin Cash Inc. is actively exploring blockchain technology and decentralized finance (DeFi) applications, aiming to enhance transparency, security, and efficiency in cannabis supply chains and financial transactions [8][11] - The company is assessing potential utility tokens, NFTs, and other crypto-related ventures that align with its long-term vision [9] Recent Acquisition - MEME COINS INC., a subsidiary of Dogecoin Cash Inc., has entered into an agreement to acquire 2 billion Dogecoin Cash (DOG) tokens, which will double its total DOG holdings to approximately 4.02 billion tokens without any dilution [1][3] - In exchange for the DOG tokens, MEME COINS INC. will issue 250,000 shares of Preferred Stock to Tipestry, Inc., maintaining its status as a wholly controlled subsidiary of DOGP [2][3] Strategic Growth Initiatives - Dogecoin Cash Inc. is committed to pursuing strategic mergers, acquisitions, and joint ventures to enhance its influence in both the cannabis and blockchain sectors [10] - The company aims to broaden its investor base and diversify revenue streams while leveraging emerging technologies to drive growth [11]

Core Insights - Tilray Medical has achieved a significant milestone in its European expansion by introducing three new medical cannabis flower varieties in Italy, becoming the first company in the country to receive official authorization from the Italian Ministry of Health for the import and distribution of its proprietary medical cannabis products [1][2]. Group 1: Product Launch and Regulatory Approval - The newly approved Tilray Medical products are now available for therapeutic use in pharmacies across Italy, highlighting the company's commitment to providing high-quality, EU-GMP certified medical cannabis [2]. - The authorization from the Italian Ministry of Health underscores the importance of medical cannabis as a therapeutic option for patients, enhancing their health and well-being [2]. Group 2: Company Background and Market Position - Tilray Medical is dedicated to providing safe and reliable access to a global portfolio of medical cannabis brands, having evolved from one of the first licensed producers in Canada to a leading supplier in Europe with EU-GMP certified production facilities in Portugal and Germany [3]. - The company operates in multiple European countries, including Germany, Italy, Portugal, Poland, and the United Kingdom, reinforcing its leadership in the European medical cannabis market [2]. Group 3: Corporate Mission and Vision - Tilray Brands, Inc. aims to be a leading global lifestyle and consumer packaged goods company, focusing on cannabis, wellness, and entertainment, with a mission to inspire joy and create memorable experiences through its diverse portfolio of over 40 brands [5].

Core Insights - Aurora Cannabis Inc. has launched two new proprietary cultivars in Poland, marking the highest potency medical cannabis products available in the country [1][2] - The new products, Farm Gas and Sourdough, are designed to meet the demand for high-quality, high-potency medical cannabis among prescribers and patients [2][3] - Aurora emphasizes its leadership in the international medical cannabis market, leveraging its scientific expertise and understanding of regulatory landscapes [3] Product Details - Farm Gas has a THC content of 27% and less than 1% CBD, with a unique aroma profile featuring notes of kerosene, diesel, and a sweet fruit sherbet finish [7] - Sourdough boasts a THC content of 29% and less than 1% CBD, characterized by sour, cake, and gasoline notes in its aroma profile [7] - Both cultivars are hang-dried and hand-finished, showcasing the company's commitment to quality [2] Company Overview - Aurora Cannabis Inc. operates in the medical and consumer cannabis markets across Canada, Europe, Australia, and New Zealand [4] - The company is known for its diverse brand portfolio, including both medical and adult-use cannabis brands [4] - Aurora holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America [4]

Core Viewpoint - Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has presented a plan aimed at revitalizing the company and enhancing shareholder value [1][6]. Shareholder Engagement - Shareholders are encouraged to vote for Apollo Capital's six director nominees using the "Gold Card" and to disregard MediPharm's "Green Card" [2][3]. - The communication emphasizes the urgency for shareholders to act in order to protect their investments [2][3]. Ownership and Influence - Apollo Capital, through its subsidiary Nobul Technologies Inc., owns approximately 3% of MediPharm's common shares, totaling 12,491,500 shares [4][6]. - The company is actively seeking to influence the board of directors through its proxy solicitation efforts [11]. Action Plan - Apollo Capital has outlined a commitment to execute an aggressive action plan aimed at increasing MediPharm's share price by over 10 times and preventing insolvency [6]. - The plan includes measures to address excessive executive compensation and rectify three years of value-destructive actions [6]. Legal and Regulatory Compliance - Apollo Capital has filed an amended dissident information circular in compliance with Canadian corporate and securities laws, detailing their director nominees and the rationale behind their actions [5][7]. - Shareholders are advised to read the amended circular carefully as it contains crucial information regarding the upcoming annual meeting [8].

Core Viewpoint - Apollo Capital and Pat McCutcheon emphasize the urgent need for change at MediPharm Lab Corp, advocating for a complete turnover at the board level to restore value for shareholders after years of mismanagement and declining share prices [1][2][5]. Group 1: Management and Governance Issues - MediPharm's share price has significantly collapsed over the past three years, while senior management has received over $10 million in compensation, raising concerns about governance and accountability [2][4]. - The current management has deviated from MediPharm's founding vision by entering the recreational cannabis market and engaging in dilutive mergers and acquisitions, which has not aligned with shareholder interests [2][3]. Group 2: Proposed Changes and Support - Apollo Capital proposes a new board of directors with relevant experience in medical cannabis and turnaround strategies, led by Regan McGee, to drive the company's stock price higher [3][4]. - Shareholders are urged to support Apollo's director nominees by voting the GOLD CARD in the upcoming AGM, as this aligns with the goal of enhancing shareholder value [4][8]. Group 3: Shareholder Engagement - Apollo Capital's business model focuses on investing in poorly managed companies and working with shareholders to secure votes for new governance that prioritizes share value growth [4][5]. - The strategic five-pillar plan for MediPharm has been made available to shareholders, outlining the steps needed to transform the company into a leading player in the medical cannabis sector [7].

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter to Shareholders from the Company's Board of Directors (the "Letter"). The Letter is a response to the amended and restated dissident proxy circular filed by Apollo on May 20, 2025, and in particular Apollo's plan for the Company. The full text of the Letter to Shareholders follows. MESSAGE FROM THE MEDIPHARM BOA ...

Core Insights - Vireo Growth Inc. has successfully completed the acquisition of WholesomeCo Cannabis and the Arches proprietary technology platform, enhancing its profitability and competitive position in the market [1][3] - The total consideration for the acquisitions amounted to $69.8 million, paid in 134.2 million Subordinate Voting Shares at a reference price of $0.52 per share [2] - The acquisition of Wholesome is based on a multiple of 4.175x the projected 2024 "Reference EBITDA" of $16 million, with performance milestones set for December 31, 2026 [2] Financial Details - The purchase price for Wholesome represents a multiple of 4.175x the expected EBITDA, indicating a strategic valuation approach [2] - Shareholders involved in the transaction have agreed to voluntary share lock-up provisions, with shares unlocking over a 33-month period [2] Strategic Implications - The acquisitions are expected to bolster Vireo's profitability profile and create competitive advantages through the proprietary technology and analytics platform [3] - The company anticipates that other pending merger transactions will also close in the second quarter of 2025, indicating ongoing growth and expansion efforts [3]